Body Pharm MOTS-C 32 Pen

The Body Pharm MOTS-C 32 pen holds 32mg of synthetic MOTS-c peptide — the largest total payload in the pen format available to South African researchers in 2026. A larger payload means fewer reorder cycles, a lower cost-per-milligram, and longer uninterrupted protocol runs.

Pen	Total Peptide Payload
Body Pharm MOTS-C Pen	32 mg

Concentration (mg/mL), fill volume, and per-click increment are vendor-disclosed on request [5]. All dosage figures cited in this guide are vendor-derived and intended for research contexts only. Not for human use.

---

Key Takeaways

• The Body Pharm MOTS-C 32mg pen has the largest total payload of the MOTS-C pen formats available, which lowers its cost-per-milligram relative to smaller formats.
• MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied for AMPK activation and metabolic flexibility in rodent models; human clinical evidence remains limited.
• No vendor has published fill volume, concentration (mg/mL), or per-click dose increments for the pen, making independent dose verification a bench-side calculation.
• MOTS-c is not SAHPRA-registered and is classified strictly as a research chemical in South Africa — for in vitro and preclinical laboratory use only.
• The 32mg payload suits extended protocols (4–9 weeks) because its larger reserve reduces reorder cycles.

---

What Is the Body Pharm MOTS-C 32 Pen?

The Body Pharm MOTS-C 32 pen is a pre-filled, multi-dose peptide delivery device containing 32mg of synthetic MOTS-c. MOTS-c is a mitochondrial-derived peptide studied for its role in insulin sensitivity and metabolic flexibility in rodent models — endpoints central to understanding mitochondrial function in metabolic disease [1]. The "32" denotes total peptide payload in milligrams, not the number of doses. Body Pharm's vendor framing presents the pen as 32 × 1mg micro-doses (vendor-stated, not independently verified) [2].

Mechanically, the pen works like any other dial-and-inject reservoir device. The researcher sets an increment, the internal plunger advances, and a measured volume is dispensed. Exact mg/mL concentration, fill volume in mL, and per-click output are not published in Body Pharm's current public materials [2]. That gap matters for procurement officers building dose-response matrices — two pens with identical mg payloads can deliver materially different volumes per click, affecting dilution series and stock-solution calculations.

At 32mg, the Body Pharm pen is the largest-payload pen format available to South African researchers, which suits extended or multi-arm protocols.

Classification is strictly research-use. SAHPRA has not registered MOTS-c as a medicine in South Africa. Unregistered peptides cannot be sold or promoted for therapeutic use; South African law requires registration or exemption before any therapeutic claim or human exposure [14][15]. For background on the peptide itself, see our MOTS-C peptide overview; for adjacent mitochondrial-energy research targets, see NAD+ research peptide.

---

MOTS-C: The Mitochondrial Peptide Explained

MOTS-c is a 16-amino-acid peptide encoded within the 12S rRNA region of mitochondrial DNA (mtDNA). That origin sets it apart from the vast majority of cellular peptides encoded by nuclear DNA, and it confers distinct signalling properties and cellular localisation patterns [1]. This structural feature has driven a decade of research interest since Lee et al. characterised it in Cell Metabolism in 2015 [1].

Property	Value
Length	16 amino acids
Genomic origin	12S rRNA region of mtDNA
Class	Mitochondrial-derived peptide (MDP)
Primary signalling pathway	AMPK activation [1]
Research models (2023–2026)	Rodent, ex vivo, limited early human [1][3]
Human Phase 2/3 efficacy data	None published as of 2026 [2][3]

Mechanism: the AMPK axis

In rodent and in vitro models, MOTS-c translocates to the nucleus under metabolic stress and activates AMP-activated protein kinase (AMPK) — the energy-sensing kinase that regulates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. The 2023 Frontiers in Endocrinology review by Jia et al. summarises the preclinical evidence. AMPK engagement correlates with improved insulin sensitivity and metabolic flexibility in mouse models of obesity and ageing [1]. These are preclinical findings only and have not been replicated in adequately powered human trials.

Evidence base: what is known and what remains unknown

No large-scale human MOTS-c trials have been completed and long-term safety data are absent as of 2026 [3]. Human evidence remains pre-therapeutic and small-sample [2].

For procurement officers, the implication is concrete. Any dosing schedule discussed later in this guide, including those derived from the Body Pharm MOTS-C pen vendor framing, rests on animal pharmacokinetics rather than human dose-response curves. Human trials have not yet established safe or effective doses in people.

Researchers working in adjacent mitochondrial-energy pathways often cross-reference NAD+ research peptide protocols. Both targets converge on AMPK and sirtuin signalling in preclinical metabolic models [1].

---

Format Advantages of the 32mg Pen

The Body Pharm MOTS-C 32mg pen is the highest-payload MOTS-C pen format stocked for South African researchers. Its practical characteristics:

Characteristic	Detail
Largest peptide reserve	32mg total — extends protocol duration without mid-study reorders
Lower cost-per-milligram	Larger payload spreads fixed unit cost across more nominal doses
Fewer reorder cycles	One pen covers 4–9 weeks at vendor-suggested 1mg increments
Single batch number	Reduces batch-to-batch variability across a full study

---

MOTS-C Pen Dosage: What the Research Suggests

No standardised clinical dosing protocol for MOTS-c in humans exists as of 2026. Human trials have not been completed and dose-response relationships remain unknown. The schedules below are vendor- and community-derived frameworks for in vitro and preclinical research planning only — not medical advice [3][4][5].

The 2023 Frontiers in Endocrinology review confirms that rigorous human dose-response data remain absent, with evidence concentrated in rodent and ex vivo models [3]. Practitioner-facing protocols circulating in 2025–2026 reference 5mg two to three times weekly or 1mg daily. These are vial-based suggestions, not pen-calibrated outputs, because pen device specifications have not been published [6].

Assuming the Body Pharm MOTS-C 32 pen delivers 32 increments of 1mg (vendor-stated, not independently verified [7]):

Schedule (1 mg per dose)	Doses per week	Pen duration	Approx. weeks covered
Daily	7	32 days	~4.5 weeks
Alternate-day	3.5	~64 days	~9 weeks
5 days on / 2 days off	5	~45 days	~6.5 weeks
3x weekly (Mon/Wed/Fri)	3	~75 days	~10.5 weeks
2x weekly	2	~112 days	~16 weeks

All five frameworks above are unverified community and vendor-derived schedules. None has been validated in a registered South African clinical trial. SAHPRA's enforcement posture treats unregistered injectable peptides as medicines requiring registration or a Section 21 exemption before any human exposure [1][2].

Why 32 doses matters for protocol design

The Body Pharm pen's 32-dose capacity gives a research protocol roughly three times the runway of a 10mg pen format and roughly twice that of a 15mg pen at equivalent per-dose assumptions. Longer supply reduces mid-study reordering and batch variability [7][13][14].

For a lab running an alternate-day in vitro exposure arm across a 9-week window, a single 32mg pen covers the schedule without a mid-study SKU change — a procurement advantage smaller formats cannot match. Researchers comparing mitochondrial peptide arms may also want to review the MOTS-C peptide overview and adjacent NAD+ research peptide protocols when designing co-treatment studies.

Treat every figure above as a planning input, not a dosing recommendation.

---

MOTS-C 32 Pen Benefits in Preclinical Research

MOTS-c is a 16-amino-acid mitochondrial-derived peptide first characterised by Lee et al. in Cell Metabolism in 2015. The bulk of its research evidence remains preclinical as of 2026 because human clinical trials have not been completed [1]. The four research domains most relevant to labs evaluating the Body Pharm MOTS-C pen for in vitro work are summarised below.

Research area	Evidence level (2026)	Key reference
AMPK activation & insulin sensitivity	Animal model + ex vivo	Lee et al. 2015; Jia et al. review 2023 [1]
Fatty acid oxidation & metabolic flexibility	Animal model (rodent)	Jia et al., Frontiers in Endocrinology 2023 [1]
Exercise physiology & mitochondrial biogenesis	Emerging; small human observational + rodent	Jia et al. 2023 [1][3]
Healthy ageing / longevity	In vitro + animal model only	Jia et al. 2023 [1]

AMPK and insulin sensitivity

The 2023 Jia et al. review in Frontiers in Endocrinology consolidates rodent data showing MOTS-c activates the AMPK pathway, improving glucose uptake and insulin sensitivity in diet-induced obese mice [1]. No registered South African Phase 2 or Phase 3 trial has reproduced these endpoints in humans as of 2026 [2][3].

Fatty acid oxidation and metabolic flexibility

Preclinical work summarised in the same 2023 review reports increased fatty acid β-oxidation and improved metabolic flexibility in treated rodents. AMPK activation shifts cellular fuel preference toward lipid catabolism, positioning MOTS-c as an exercise-mimetic candidate in animal models [1]. Vendor listings that frame this as a confirmed human metabolic effect are repeating vendor copy, not primary literature — treat them accordingly during vendor qualification.

Exercise physiology and mitochondrial biogenesis

This is the most active emerging area. Small human observational studies measure endogenous MOTS-c against exercise capacity, alongside continued rodent work on mitochondrial biogenesis markers. Exercise is a known MOTS-c stimulus [1][3]. Researchers designing co-treatment arms with NAD+ research peptide protocols are working in an area where mechanistic overlap is plausible. Human dose-response data does not yet exist.

Healthy ageing and longevity

Longevity-relevant findings remain confined to in vitro assays and rodent lifespan/healthspan models as of 2026 [3]. Large-scale human MOTS-c trials with published dosing-efficacy outcomes have not been completed [2][3].

Human clinical evidence across all four domains remains limited in 2026. No figure above should be read as a human-use endorsement.

---

Regulatory Status in South Africa (2026)

MOTS-C peptide pens are not registered medicines with SAHPRA as of 2026. They occupy a research-chemical classification under South African law and cannot lawfully be sold, advertised, or supplied for human therapeutic use [9][10]. Procurement is permissible only for bona fide in vitro and preclinical laboratory research. Importation, labelling, and any human exposure would trigger Medicines and Related Substances Act obligations [9].

SAHPRA's enforcement notices have specifically referenced unregistered injectable peptides, signalling active scrutiny of this category [10]. Any therapeutic-use access would require either product registration or a Section 21 named-patient or research exemption [9].

What this means for procurement officers

Before placing an order for the Body Pharm MOTS-C pen, verify the current SAHPRA position directly at sahpra.org.za. Confirm that your institution's ethics and biosafety approvals explicitly cover mitochondrial-derived peptides. Document the in vitro or preclinical scope on the purchase order because regulatory compliance requires clear institutional oversight [9][10].

This page is not legal advice. All products discussed are framed for laboratory research only, consistent with the MOTS-C peptide overview disclaimer applied across the jcsg.org/za peptide catalogue, including adjacent listings such as the NAD+ research peptide entry.

---

Which Protocols Suit the 32mg Pen?

The Body Pharm MOTS-C 32 pen suits research protocols that need a long continuous dosing window and a low cost-per-milligram in the MOTS-C pen format. At 32mg total peptide load, it carries the largest reserve of any pen SKU stocked, which means fewer reorder cycles for extended in vitro or preclinical timelines [3][6][11].

Match the pen to the protocol

Pick the Body Pharm 32mg pen when:

• Your study design runs 4–9 weeks at vendor-suggested micro-dose increments.
• Procurement is consolidating SKUs to reduce per-order freight and import handling — fewer orders mean less administrative overhead.
• A single batch number across the full study is required to improve data integrity and minimise batch-to-batch variation [10].

All formats remain research-chemical classifications under South African law. For wider mitochondrial-peptide context, see the MOTS-C peptide overview and adjacent NAD+ research peptide entry. Dose counts and durations above are vendor-derived and not medical advice.

---

Related Mitochondrial and Metabolic Peptides

Four peptides on the jcsg.org/za catalogue overlap with MOTS-C research scope, spanning mitochondrial energetics, cellular repair, and tissue regeneration.

Peptide	Research overlap with MOTS-C
NAD+	Co-studied in mitochondrial bioenergetics and metabolic flexibility models. Both pathways converge on AMPK and sirtuin signalling [3].
BPC-157	Investigated in cellular repair and gut-tissue models that frequently sit alongside metabolic-stress assays.
GHK-Cu	Studied in cellular regeneration and oxidative-stress contexts, an adjacent endpoint set to mitochondrial work.
TB500	Examined in tissue repair and recovery assays; often paired with metabolic peptides in preclinical protocol design.

For the parent category, see the MOTS-C peptide overview. All entries above are classified as research chemicals in South Africa and are not approved for human or veterinary use [1].

---

Frequently Asked Questions